Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NPD-0614
- Development stage
- Preclinical
- Lead developer
- Nogra Pharma
- Modality
- Small Molecules
- Administration
- Intraperitoneal
01
Overview
NPD-0614 is a preclinical-stage small molecule drug candidate developed by Nogra Pharma. It functions as a selective androgen/hormone receptor modulator (SAhRM) targeting the androgen receptor. The compound is being investigated for the treatment of immune-inflammatory-mediated diseases. As a SAhRM, NPD-0614 is designed to provide tissue-selective modulation of androgen receptor signaling, aiming to harness the anti-inflammatory properties of androgen signaling while avoiding the systemic side effects typically associated with conventional androgen therapies.
02
Targets
AHR (Aryl hydrocarbon receptor)AR (Adrenergic receptors)
Beyond the preview
Go deeper on NPD-0614.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NPD-0614.